Lipid accumulation product is a valid predictor of hepatic steatosis and nonalcoholic fatty liver disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Yi M, Peng W, Feng X et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment. Pharmacol. Ther. 56(7), 1119–1130 (2022).
  MedlineGoogle Scholar
• 2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4), 1335–1347 (2023).
  MedlineGoogle Scholar
• 3. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184(10), 2537–2564 (2021).
  Medline CASGoogle Scholar
• 4. Mcpherson S, Armstrong MJ, Cobbold JF et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol. Hepatol. 7(8), 755–769 (2022).
  MedlineGoogle Scholar
• 5. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 397(10290), 2212–2224 (2021).
  Medline CASGoogle Scholar
• 6. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1), 328–357 (2018).
  MedlineGoogle Scholar
• 7. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc. Disord. 5(1), 1–10 (2005).
  MedlineGoogle Scholar
• 8. Shu L, Zhao Y, Shen Y, Jia L, Zhang J. Interaction analysis of lipid accumulation product and family history of diabetes on impaired fasting glucose and diabetes risk in population with normotension in Eastern China: a community-based cross-sectional survey. Arch. Public Health 80(1), 217 (2022).
  MedlineGoogle Scholar
• 9. Van Der Poorten D, Milner KL, Hui J et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48(2), 449–457 (2008).
  MedlineGoogle Scholar
• 10. Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J. Gastroenterol. 25(24), 3009–3020 (2019).
  Medline CASGoogle Scholar
• 11. Özcabı B, Demirhan S, Akyol M, Öztürkmen Akay H, Güven A. Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity. Korean J. Pediatr. 62(12), 450–455 (2019).
  MedlineGoogle Scholar
• 12. Ji BL, Li R, Zhang SH et al. The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. Nutr. Res. 32(8), 581–587 (2012).
  Medline CASGoogle Scholar
• 13. Zhang Y, Li B, Liu N, Wang P, He J. Evaluation of different anthropometric indicators for screening for nonalcoholic fatty liver disease in elderly individuals. Int. J. Endocrinol. 2021, 6678755 (2021).
  MedlineGoogle Scholar
• 14. Liu Y, Wang W. Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults. Lipids Health Dis. 21(1), 8 (2022).
  Medline CASGoogle Scholar
• 15. Ebrahimi M, Seyedi SA, Nabipoorashrafi SA et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 22(1), 41 (2023).
  Medline CASGoogle Scholar
• 16. Preciado-Puga MC, Ruiz-Noa Y, Garcia-Ramirez JR et al. Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures. Ann. Hepatol. 21, 100264 (2021). •• Explores the predictive ability of lipid accumulation product (LAP), FLI and right liver index diameter for nonalcoholic steatohepatitis (NASH; NAS ≥5) in a Mexican population.
  MedlineGoogle Scholar
• 17. Li R, Liu J, Han P, Shi R, Zhao L, Li J. Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. J. Gastroenterol. Hepatol. 38(8), 1316–1324 (2023). •• This paper explores the predictive ability of LAP, Chinese visceral adiposity index and other noninvasive indicators for NASH in a Chinese population.
  MedlineGoogle Scholar
• 18. Agganis B, Lee D, Sepe T. Liver enzymes: no trivial elevations, even if asymptomatic. Cleveland Clinic J. Med. 85(8), 612–617 (2018).
  MedlineGoogle Scholar
• 19. Petta S, Amato M, Cabibi D et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 52(5), 1543–1552 (2010).
  MedlineGoogle Scholar
• 20. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 6(4), 299–304 (2008).
  Medline CASGoogle Scholar
• 21. Xu C, Ma Z, Wang Y et al. Visceral adiposity index as a predictor of NAFLD: A prospective study with 4-year follow-up. Liver Int. 38(12), 2294–2300 (2018).
  MedlineGoogle Scholar
• 22. Zhang S, Du T, Zhang J et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 16(1), 15 (2017).
  MedlineGoogle Scholar
• 23. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313–1321 (2005).
  MedlineGoogle Scholar
• 24. Amato MC, Giordano C, Galia M et al. Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33(4), 920–922 (2010).
  MedlineGoogle Scholar
• 25. Guerrero-Romero F, Simental-Mendía LE, GonzáLez-Ortiz M et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Compar. Euglycemic-Hyperinsulinemic Clamp 95(7), 3347–3351 (2010).
  CASGoogle Scholar
• 26. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 40(10), 1209–1222 (2014).
  Medline CASGoogle Scholar
• 27. Petta S, Amato MC, Di Marco V et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 35(2), 238–247 (2012).
  Medline CASGoogle Scholar
• 28. Vongsuvanh R, George J, Mcleod D, Van Der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J. Hepatol. 57(2), 392–398 (2012).
  MedlineGoogle Scholar
• 29. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am. J. Gastroenterol. 94(10), 3010–3014 (1999).
  Medline CASGoogle Scholar
• 30. Pirimoğlu B, Sade R, Polat G, İşlek A, Kantarcı M. Analysis of correlation between liver fat fraction and AST and ALT levels in overweight and obese children by using new magnetic resonance imaging technique. Turkish J. Gastroenterol. 31(2), 156–162 (2020).
  Google Scholar
• 31. Cuthbertson DJ, Weickert MO, Lythgoe D et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur. J. Endocrinol. 171(5), 561–569 (2014).
  Medline CASGoogle Scholar
• 32. Weta IW, Mahadewa TGB, Sutirtayasa WP, Subawa A, Sitanggang FP, Widyadharma IPE. The comparison of simple anthropometric and biochemical parameters for predicting liver steatosis in obese Balinese Young women. Open Access Macedon. J. Med. Sci. 6(11), 2062–2066 (2018).
  MedlineGoogle Scholar
• 33. Goessling W, Massaro JM, Vasan RS, D'agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135(6), 1935–1944; e1931 (2008).
  Medline CASGoogle Scholar
• 34. Song K, Lee HW, Choi HS et al. Comparison of the modified TyG indices and other parameters to predict non-alcoholic fatty liver disease in youth. Biology 11(5), 685 (2022).
  Medline CASGoogle Scholar
• 35. Rivière B, Jaussent A, Macioce V et al. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabet. Metab. 48(4), 101345 (2022).
  CASGoogle Scholar
• 36. Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr. Metab. 14, 49 (2017).
  Google Scholar
• 37. Tantanavipas S, Vallibhakara O, Sobhonslidsuk A et al. Abdominal obesity as a predictive factor of nonalcoholic fatty liver disease assessed by ultrasonography and transient elastography in polycystic ovary syndrome and healthy women. BioMed Res. Int. 2019, 9047324 (2019).
  MedlineGoogle Scholar
• 38. Berk PD, Verna EC. Nonalcoholic fatty liver disease: lipids and insulin resistance. Clin. Liver Dis. 20(2), 245–262 (2016).
  MedlineGoogle Scholar
• 39. Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J. Gastrointest. Liver Dis. 28(4), 427–431 (2019).
  MedlineGoogle Scholar
• 40. Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J. Gastroenterol. 15(15), 1863–1868 (2009).
  Medline CASGoogle Scholar
• 41. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am. Family Phys. 96(11), 709–715 (2017).
  MedlineGoogle Scholar
• 42. Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of non-alcoholic fatty liver disease. Lipids Health Dis. 20(1), 134 (2021). • Suggests that triglyceride–glucose index-related parameters, LAP, HSI, body mass index and waist circumference appear to be good predictors of ultrasound-proven nonalcoholic fatty liver disease.
  Medline CASGoogle Scholar
• 43. Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3), 837–845 (1988).
  Medline CASGoogle Scholar